Trial Profile

CMV-MVA Triplex Vaccination of Stem Cell Donors to Enhance CMV Specific Immunity and Prevent CMV Viremia in Recipients After Stem Cell Transplant

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 01 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MVA CMV (Primary)
Indications Cytomegalovirus infections
Focus Adverse reactions; Pharmacodynamics; Proof of concept; Therapeutic Use

26 Mar 2025 Planned End Date changed from 18 Dec 2024 to 27 Aug 2025.
27 Jan 2025 According to a Fortress Biotech media release, study is being conducted across three nationally recognized transplant centers in the United States (City of Hope in Duarte, California; Brigham & Women's Hospital and the Dana-Farber Cancer Institute in Boston; and Northside Medical Center in suburban Atlanta).
27 Jan 2025 According to a Fortress Biotech media release, data from this study presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com